Stay up to date with news and events
Roche Phase II GENERATION HD2 study underway
February 16, 2023
Roche released a community letter last month, detailing how their Phase II clinical trial to study the huntingtin-lowering drug, tominersen, is now underway. Learn more…
Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
December 9, 2022
The pharmaceutical company Novartis has released a community update which announces that they are ending development of branaplam, a huntingtin lowering drug, for possible treatment…
uniQure gets the green light to resume testing HD gene therapy
November 5, 2022
In August 2022, uniQure announced a pause in new recruitment for their trial of AMT-130, an HD gene therapy delivered via brain surgery. The decision…
Update on the PTC Therapeutics PIVOT-HD Trial
November 4, 2022
Recruitment of participants into the US arm of the PTC Therapeutics PIVOT-HD trial has been paused. Since this announcement, there have been a lot of…
Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
October 2, 2022
In the past week or so, during and following a big HD research conference, two companies developing medicines for Huntington’s disease announced news about their…